Research article
Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction
- Economic evaluation (state-transition Markov model)
- lifetime horizon
- US health care sector perspective
- 3% annual discounting
- probabilistic sensitivity analysis
Authors' conclusion
Results of this economic evaluation suggest that at 2022 drug prices, adding an SGLT2-I to standard of care was of intermediate or low economic value compared with standard of care in US adults with HFpEF.
Study context
- Population
- Simulated US cohort with heart failure with preserved ejection fraction (HFpEF), characteristics similar to EMPEROR-Preserved and DELIVER participantssimulated cohort
- Participants
- 12,251 participants
- Comparison
- Standard of care plus SGLT2-I vs standard of care
- Outcome
- QALYs, direct medical costs (2022 US dollars) and ICER
- Follow-up
- Lifetime
Main finding
As reported in the abstract
Lifetime QALYs, direct medical costs (2022 US dollars) and ICER
- SGLT2-I
- incremental quality-adjusted life-years (QALYs) 0.19 QALYs
- SGLT2-I
- incremental cost $26 300 2022 US dollars
- Incremental cost-effectiveness ratio (ICER), SGLT2-I added to standard of care vs standard of care
- $141 200 per QALY gained
- Probabilistic iterations indicating intermediate value (of 1000)
- 59.1%
- Probabilistic iterations indicating low value (of 1000)
- 40.9%
Further findings
| Outcome | ICER (per QALY gained) |
|---|---|
| Sensitivity analysis: ICER if SGLT2-I has no effect on mortality · no effect on mortality assumed | $373 400 |
Sensitivity analysis: ICER if SGLT2-I has no effect on mortality
- ICER most sensitive to SGLT2-I costs and effect on CV death
Original publication
Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. Published 1 May 2023. doi:10.1001/jamacardio.2023.0077
Summarised from the published abstract; every number is checked against it